Cargando…
Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study
Despite some variability in ideal serum Adalimumab (ADA) concentrations, there is increasing evidence that higher concentrations of anti-TNF-α agents can be associated with sustained efficacy, and low or undetectable levels may lead to loss of response. This study aims to correlate serum ADA concent...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967155/ https://www.ncbi.nlm.nih.gov/pubmed/36839908 http://dx.doi.org/10.3390/pharmaceutics15020586 |
_version_ | 1784897194647617536 |
---|---|
author | de Souza, Letícia Rodrigues Magro, Daniela Oliveira Teixeira, Fábio Vieira Parra, Rogério Serafim Miranda, Eron Fábio Féres, Omar Saad-Hossne, Rogério Soares Prates Herrerias, Giedre Nisihara, Renato Mitsunori Coy, Claudio Saddy Rodrigues Sassaki, Ligia Yukie Kotze, Paulo Gustavo |
author_facet | de Souza, Letícia Rodrigues Magro, Daniela Oliveira Teixeira, Fábio Vieira Parra, Rogério Serafim Miranda, Eron Fábio Féres, Omar Saad-Hossne, Rogério Soares Prates Herrerias, Giedre Nisihara, Renato Mitsunori Coy, Claudio Saddy Rodrigues Sassaki, Ligia Yukie Kotze, Paulo Gustavo |
author_sort | de Souza, Letícia Rodrigues |
collection | PubMed |
description | Despite some variability in ideal serum Adalimumab (ADA) concentrations, there is increasing evidence that higher concentrations of anti-TNF-α agents can be associated with sustained efficacy, and low or undetectable levels may lead to loss of response. This study aims to correlate serum ADA concentrations with clinical and endoscopic activity in patients with Crohn’s disease (CD). A cross-sectional and multicentric study was performed with patients with CD, who used ADA for at least 24 weeks. Patients were allocated into groups according to the presence of clinical or endoscopic disease activity. Serum ADA concentrations were measured and compared between groups. Overall, 89 patients were included. A total of 27 patients had clinically active CD and 62 were in clinical remission. Forty patients had endoscopic disease activity and 49 were in endoscopic remission. The mean serum ADA concentration was 10.2 μg/mL in patients with clinically active CD and 14.3 μg/mL in patients in clinical remission (p = 0.395). The mean serum ADA concentration in patients with endoscopic activity was 11.3 μg/mL as compared to 14.5 μg/mL in those with endoscopic remission (p = 0.566). There was no difference between serum ADA concentrations regarding clinical or endoscopic activity in CD, as compared to patients in remission |
format | Online Article Text |
id | pubmed-9967155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99671552023-02-26 Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study de Souza, Letícia Rodrigues Magro, Daniela Oliveira Teixeira, Fábio Vieira Parra, Rogério Serafim Miranda, Eron Fábio Féres, Omar Saad-Hossne, Rogério Soares Prates Herrerias, Giedre Nisihara, Renato Mitsunori Coy, Claudio Saddy Rodrigues Sassaki, Ligia Yukie Kotze, Paulo Gustavo Pharmaceutics Article Despite some variability in ideal serum Adalimumab (ADA) concentrations, there is increasing evidence that higher concentrations of anti-TNF-α agents can be associated with sustained efficacy, and low or undetectable levels may lead to loss of response. This study aims to correlate serum ADA concentrations with clinical and endoscopic activity in patients with Crohn’s disease (CD). A cross-sectional and multicentric study was performed with patients with CD, who used ADA for at least 24 weeks. Patients were allocated into groups according to the presence of clinical or endoscopic disease activity. Serum ADA concentrations were measured and compared between groups. Overall, 89 patients were included. A total of 27 patients had clinically active CD and 62 were in clinical remission. Forty patients had endoscopic disease activity and 49 were in endoscopic remission. The mean serum ADA concentration was 10.2 μg/mL in patients with clinically active CD and 14.3 μg/mL in patients in clinical remission (p = 0.395). The mean serum ADA concentration in patients with endoscopic activity was 11.3 μg/mL as compared to 14.5 μg/mL in those with endoscopic remission (p = 0.566). There was no difference between serum ADA concentrations regarding clinical or endoscopic activity in CD, as compared to patients in remission MDPI 2023-02-09 /pmc/articles/PMC9967155/ /pubmed/36839908 http://dx.doi.org/10.3390/pharmaceutics15020586 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article de Souza, Letícia Rodrigues Magro, Daniela Oliveira Teixeira, Fábio Vieira Parra, Rogério Serafim Miranda, Eron Fábio Féres, Omar Saad-Hossne, Rogério Soares Prates Herrerias, Giedre Nisihara, Renato Mitsunori Coy, Claudio Saddy Rodrigues Sassaki, Ligia Yukie Kotze, Paulo Gustavo Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study |
title | Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study |
title_full | Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study |
title_fullStr | Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study |
title_full_unstemmed | Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study |
title_short | Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study |
title_sort | adalimumab serum concentrations, clinical and endoscopic disease activity in crohn’s disease: a cross-sectional multicentric latin american study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967155/ https://www.ncbi.nlm.nih.gov/pubmed/36839908 http://dx.doi.org/10.3390/pharmaceutics15020586 |
work_keys_str_mv | AT desouzaleticiarodrigues adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT magrodanielaoliveira adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT teixeirafabiovieira adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT parrarogerioserafim adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT mirandaeronfabio adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT feresomar adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT saadhossnerogerio adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT soarespratesherreriasgiedre adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT nisihararenatomitsunori adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT coyclaudiosaddyrodrigues adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT sassakiligiayukie adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy AT kotzepaulogustavo adalimumabserumconcentrationsclinicalandendoscopicdiseaseactivityincrohnsdiseaseacrosssectionalmulticentriclatinamericanstudy |